Osterweis Capital Management Inc. Sells 48,570 Shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT)

Osterweis Capital Management Inc. trimmed its holdings in shares of PROCEPT BioRobotics Co. (NASDAQ:PRCT - Free Report) by 35.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 87,745 shares of the company's stock after selling 48,570 shares during the period. Osterweis Capital Management Inc. owned 0.17% of PROCEPT BioRobotics worth $7,065,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Signaturefd LLC boosted its position in shares of PROCEPT BioRobotics by 26.7% in the 4th quarter. Signaturefd LLC now owns 689 shares of the company's stock worth $55,000 after purchasing an additional 145 shares during the last quarter. Naviter Wealth LLC grew its position in shares of PROCEPT BioRobotics by 6.0% during the 4th quarter. Naviter Wealth LLC now owns 3,089 shares of the company's stock worth $249,000 after buying an additional 176 shares during the period. Amundi increased its stake in shares of PROCEPT BioRobotics by 0.9% in the 4th quarter. Amundi now owns 20,143 shares of the company's stock valued at $1,742,000 after acquiring an additional 183 shares during the last quarter. Arizona State Retirement System raised its position in shares of PROCEPT BioRobotics by 1.5% in the 4th quarter. Arizona State Retirement System now owns 14,285 shares of the company's stock valued at $1,150,000 after acquiring an additional 218 shares during the period. Finally, KRS Capital Management LLC boosted its stake in PROCEPT BioRobotics by 0.5% during the 4th quarter. KRS Capital Management LLC now owns 46,455 shares of the company's stock worth $3,741,000 after acquiring an additional 225 shares during the last quarter. 89.46% of the stock is owned by institutional investors.

PROCEPT BioRobotics Stock Down 1.0 %

NASDAQ PRCT traded down $0.52 during trading on Tuesday, hitting $52.92. The stock had a trading volume of 333,723 shares, compared to its average volume of 784,521. PROCEPT BioRobotics Co. has a 12 month low of $47.04 and a 12 month high of $103.81. The company has a debt-to-equity ratio of 0.21, a quick ratio of 5.07 and a current ratio of 6.02. The company's 50-day moving average price is $58.90 and its two-hundred day moving average price is $74.53. The company has a market capitalization of $2.90 billion, a PE ratio of -27.14 and a beta of 1.09.

PROCEPT BioRobotics (NASDAQ:PRCT - Get Free Report) last issued its quarterly earnings results on Tuesday, February 25th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.01). The business had revenue of $68.24 million for the quarter, compared to the consensus estimate of $66.79 million. PROCEPT BioRobotics had a negative return on equity of 38.57% and a negative net margin of 50.07%. As a group, sell-side analysts forecast that PROCEPT BioRobotics Co. will post -1.75 EPS for the current year.

Insider Transactions at PROCEPT BioRobotics

In related news, CFO Kevin Waters sold 733 shares of the company's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $41,824.98. Following the completion of the sale, the chief financial officer now owns 107,991 shares of the company's stock, valued at $6,161,966.46. This represents a 0.67 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Reza Zadno sold 5,475 shares of the firm's stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $57.06, for a total transaction of $312,403.50. Following the completion of the transaction, the chief executive officer now directly owns 173,070 shares in the company, valued at approximately $9,875,374.20. This represents a 3.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 6,455 shares of company stock worth $368,322 in the last 90 days. Corporate insiders own 17.40% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the stock. Morgan Stanley reduced their price target on shares of PROCEPT BioRobotics from $105.00 to $95.00 and set an "overweight" rating on the stock in a research report on Wednesday, February 26th. Truist Financial lowered their price target on PROCEPT BioRobotics from $90.00 to $70.00 and set a "buy" rating for the company in a report on Friday, April 11th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $91.43.

PROCEPT BioRobotics Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).